TRVI vs. CDT, ZVRA, HOWL, VERU, IXHL, ATOS, MACK, IVA, OGI, and ACRV
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Conduit Pharmaceuticals (CDT), Zevra Therapeutics (ZVRA), Werewolf Therapeutics (HOWL), Veru (VERU), Incannex Healthcare (IXHL), Atossa Therapeutics (ATOS), Merrimack Pharmaceuticals (MACK), Inventiva (IVA), Organigram (OGI), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical preparations" industry.
Conduit Pharmaceuticals (NASDAQ:CDT) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
Conduit Pharmaceuticals has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Trevi Therapeutics received 78 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users.
3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 23.5% of Conduit Pharmaceuticals shares are owned by company insiders. Comparatively, 27.5% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Trevi Therapeutics' return on equity of 0.00% beat Conduit Pharmaceuticals' return on equity.
Trevi Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 206.86%. Given Conduit Pharmaceuticals' higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Conduit Pharmaceuticals.
In the previous week, Trevi Therapeutics had 10 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 12 mentions for Trevi Therapeutics and 2 mentions for Conduit Pharmaceuticals. Trevi Therapeutics' average media sentiment score of 0.69 beat Conduit Pharmaceuticals' score of 0.41 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media.
Summary
Trevi Therapeutics beats Conduit Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
